Tanner Stages of Sexual Maturation
Overview and Clinical Significance
Tanner staging is a standardized five-stage system for assessing pubertal development based on physical examination of secondary sexual characteristics, with distinct criteria for males and females. This system provides a more accurate assessment of biological maturity than chronological age alone, which is critical for medication dosing, sports participation decisions, and identifying pubertal abnormalities 1.
Tanner Stages in Females
Breast Development (B1-B5)
- Stage 1 (Prepubertal): No breast tissue; only the papilla is elevated 2
- Stage 2 (Thelarche): Breast bud stage with elevation of breast and papilla as a small mound; areolar diameter enlarges. This is the first sign of puberty in females (mean age 10.3 years) 1, 3
- Stage 3: Further enlargement of breast and areola with no separation of their contours 2
- Stage 4: Projection of areola and papilla to form a secondary mound above the level of the breast 2
- Stage 5 (Adult): Mature breast with projection of papilla only; areola recedes to general contour of breast 2
Pubic Hair Development in Females (PH1-PH5)
- Stage 1: No pubic hair 2
- Stage 2: Sparse growth of long, slightly pigmented hair along the labia (mean age 10.7 years) 3
- Stage 3: Darker, coarser, and more curled hair spreading sparsely over the mons pubis 2
- Stage 4: Adult-type hair but limited in area 2
- Stage 5: Adult distribution in quantity and type, with spread to medial thighs 2
Key Milestones in Females
- Peak height velocity occurs during Tanner stages 2-3 (mid-puberty), before menarche 1
- Menarche typically occurs at breast stage 3-4 (mean age 12.4 years) 3
- Axillary hair (stage AH2) appears at mean age 12.5 years 3
Tanner Stages in Males
Genital Development (G1-G5)
- Stage 1 (Prepubertal): Testes, scrotum, and penis are of childhood size 2
- Stage 2: Testicular enlargement to ≥4 mL volume (measured by orchidometer) is the first sign of puberty in males (mean age 11.3 years). Scrotum enlarges and changes in texture; penis size unchanged 1, 4
- Stage 3: Further growth of testes and scrotum; penis increases in length 2
- Stage 4: Continued growth of testes and scrotum; penis increases in length and circumference; glans develops 2
- Stage 5 (Adult): Adult size and shape of genitalia 2
Pubic Hair Development in Males (PH1-PH5)
- Stage 1: No pubic hair 2
- Stage 2: Sparse growth of long, slightly pigmented hair at base of penis (mean age 12.0 years) 3, 4
- Stage 3: Darker, coarser, and more curled hair spreading over the pubis. This stage marks the peak of pubertal growth spurt in males (mean age 13.5 years) 5, 4
- Stage 4: Adult-type hair but limited in area 2
- Stage 5: Adult distribution with spread to medial thighs 2
Key Milestones in Males
- Testicular volume <4 mL at age 14 years warrants referral to pediatric endocrinology for delayed puberty 1
- Axillary hair (stage AH2) appears at mean age 13.8 years 3
- Peak height velocity occurs later than in females, typically during Tanner stage 3-4 5
Critical Clinical Distinctions
First Signs of Puberty
- Females: Breast development (thelarche), not pubic hair 1
- Males: Testicular enlargement to ≥4 mL, not pubic hair 1
- Pubic hair represents adrenarche (adrenal androgen production) rather than true activation of the hypothalamic-pituitary-gonadal axis 1
Assessment Timing and Method
- Begin annual Tanner staging at age 10 years to establish baseline and monitor progression 1
- Physical examination by a trained clinician remains the gold standard 2
- Self-assessment using standardized photographs shows excellent agreement with physician ratings (kappa coefficients 0.67-0.91) and can be used in research settings or when physical examination is not feasible 6, 7
Clinical Applications Beyond Growth Assessment
Delayed Puberty Referral Criteria
- Females: Breast stage <B2 at age 13.5 years, or no menarche by age 16 years despite breast development 2, 1
- Males: Testicular volume <4 mL at age 14 years 1
- Either sex: Failure to progress through puberty for ≥12 months 2
Medication Dosing and Safety
- Use Tanner stage rather than chronological age alone for medication dosing decisions, as physiologic maturity varies significantly among same-aged children 1
- Insulin resistance peaks during mid-puberty (Tanner stages 2-4), making metabolic monitoring particularly important during this window 1
- Statin therapy in adolescents requires monitoring of Tanner staging every 3-6 months 1
Sports Participation
- Contact and collision sports placement should be based on Tanner stage rather than chronological age to reduce injury risk 1
- Weight training with heavier weights should only be pursued after reaching Tanner stage 5 (physical maturity) 1
Laboratory Interpretation
- IGF-1 levels must be interpreted using Tanner stage-matched, age-adjusted, and sex-adjusted normal ranges 1
- Growth hormone suppression testing varies by pubertal stage, with highest GH levels occurring in mid-puberty (Tanner stages 2-3), particularly in girls 1
Common Pitfalls to Avoid
- Do not rely on pubic hair development as the first sign of puberty; it represents adrenarche, not gonadarche 1
- Do not use chronological age alone for clinical decisions when Tanner staging is more appropriate 1
- Do not diagnose PCOS using ultrasound in girls whose gynecologic age is <8 years after menarche, as multi-follicular ovaries are common in this developmental stage 2
- Do not assume all pubertal progression is normal; monitor annually and refer if progression stalls for ≥12 months 2, 1
- In females, recognize that peak height velocity occurs during Tanner stages 2-3, before menarche, so growth potential is limited after menarche 1
Special Considerations
Transgender Youth
- Updated Endocrine Society guidelines allow earlier medical intervention for transgender youth beginning with pubertal hormone suppression once children first exhibit changes of puberty (Tanner stage 2) 8
Monitoring in Chronic Disease
- Before initiating growth hormone therapy in children with chronic kidney disease, pubertal status according to Tanner staging must be assessed 1
- Approximately 8-10% of female survivors of pediatric cancer develop premature ovarian insufficiency, making Tanner staging essential for monitoring 2